Sökning: WFRF:(Ossenkoppele Gert)
> (2019) >
Prognosis of patien...
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
-
- Lauseker, Michael (författare)
- Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany
-
- Bachl, Katharina (författare)
- Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany
-
- Turkina, Anna (författare)
- Natl Res Ctr Hematol, Moscow, Russia
-
visa fler...
-
- Faber, Edgar (författare)
- Palacky Univ, Univ Hosp, Dept Hematol Oncol, Olomouc, Czech Republic
-
- Prejzner, Witold (författare)
- Med Univ Gdansk, Dept Hematol, Gdansk, Poland
-
- Strömberg, Ulla Ohlsson (författare)
- Uppsala universitet,Hematologi
-
- Baccarani, Michele (författare)
- Univ Bologna, Dept Hematol & Oncol L&A, Bologna, Italy
-
- Lomaia, Elza (författare)
- Almazov Med Res Ctr, Clin Oncol Res Dept Oncol & Hematol, St Petersburg, Russia
-
- Zackova, Daniela (författare)
- Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic;Masaryk Univ, Brno, Czech Republic
-
- Ossenkoppele, Gert (författare)
- Vrije Univ Amsterdam Med Ctr, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands
-
- Griskevicius, Laimonas (författare)
- Vilnius Univ, Vilnius Univ Hosp Santaros Klin, Vilnius, Lithuania;Vilnius Univ, Inst Clin Med, Vilnius, Lithuania
-
- Schubert-Fritschle, Gabriele (författare)
- Ludwig Maximilians Univ Munchen, Munich Canc Registry, Munich, Germany
-
- Sacha, Tomasz (författare)
- Jagiellonian Univ Hosp, Chair & Dept Hematol, Krakow, Poland
-
- Heibl, Sonja (författare)
- Klinikum Wels Grieskirchen, Dept Internal Med 4, Wels, Austria
-
- Koskenvesa, Perttu (författare)
- Helsinki Univ Hosp, Ctr Canc, Helsinki, Finland;Univ Helsinki, Hematol Res Unit, Helsinki, Finland
-
- Bogdanovic, Andrija (författare)
- Univ Belgrade, Clin Hematol CCS, Belgrade, Serbia;Univ Belgrade, Fac Med, Belgrade, Serbia
-
- Clark, Richard E. (författare)
- Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England
-
- Guilhot, Joelle (författare)
- CHU Poitiers, Clin Invest Ctr, INSERM, CIC 1402, Poitiers, France
-
- Hoffmann, Verena S. (författare)
- Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany
-
- Hasford, Joerg (författare)
- Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany
-
- Hochhaus, Andreas (författare)
- Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol Onkol, Jena, Germany
-
- Pfirrmann, Markus (författare)
- Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Marchioninistr 15, D-81377 Munich, Germany
-
visa färre...
-
(creator_code:org_t)
- 2019-09-14
- 2019
- Engelska.
-
Ingår i: American Journal of Hematology. - : WILEY. - 0361-8609 .- 1096-8652. ; 94:11, s. 1236-1243
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.onlineli...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lauseker, Michae ...
-
Bachl, Katharina
-
Turkina, Anna
-
Faber, Edgar
-
Prejzner, Witold
-
Strömberg, Ulla ...
-
visa fler...
-
Baccarani, Miche ...
-
Lomaia, Elza
-
Zackova, Daniela
-
Ossenkoppele, Ge ...
-
Griskevicius, La ...
-
Schubert-Fritsch ...
-
Sacha, Tomasz
-
Heibl, Sonja
-
Koskenvesa, Pert ...
-
Bogdanovic, Andr ...
-
Clark, Richard E ...
-
Guilhot, Joelle
-
Hoffmann, Verena ...
-
Hasford, Joerg
-
Hochhaus, Andrea ...
-
Pfirrmann, Marku ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
American Journal ...
- Av lärosätet
-
Uppsala universitet